Breaking Finance News

Citigroup Inc. downgraded Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to Sell in a report released today.

Just yesterday Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) traded -7.01% lower at $78.29. Ultragenyx Pharmaceutical Inc’s 50-day moving average is $69.53 and its 200-day moving average is $64.95. The last stock price is up 20.54% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 898,067 shares of RARE traded, up from an avg. volume of 623,981

Citigroup Inc. has downgraded Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to Sell in a report released on 11/30/2016.

Previously on 03/08/2016, Robert W. Baird released a statement about Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) increased the target price from $0.00 to $85.00. At the time, this indicated a possible upside of 0.29%.

Performance Chart

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

With a total market value of $0, Ultragenyx Pharmaceutical Inc has with a one year low of $46.52 and a one year high of $117.12 .

A total of 15 equity analysts have released a ratings update on RARE. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $96.40.

Brief Synopsis About Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *